# US 2019/0376064 A1 · Genetic and Pharmacological Transcriptional Upregulation of the Repressed FXN Gene as a Therapeutic Strategy for Friedreich Ataxia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376064 A1
- Document ID: US20190376064A1
- Status: Published application
- Kind: A1
- Application number: 16/487,876
- Filed: 2018-02-14
- Published: 2019-12-12
- Earliest claimed: 2017-02-28
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Michael R. Green; Minggang Fang
- Web page: https://patentgrep.com/patent/US20190376064A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/381: having five-membered rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- C07K 14/47: from mammals
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods of treating subjects having disorders associated with mutations in the FXN gene and/or having reduced expression of frataxin protein, e.g., Friedreich ataxia (FA). Generally, the methods include administering a therapeutically effective amount of an agent that increases expression of frataxin protein as described herein, e.g., an inhibitor of a FXN Repressing Factor (FXN-RF).

## Claims

### Claim 1

A method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of a FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7.

### Claim 2 (depends on 1)

The method of claim 1, wherein the small molecule is a molecule shown in Table 1 or FIGS. 7A-7F.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has Friedreich ataxia (FA).

### Claim 4

A method of treating a subject having a disorder associated with a mutation in the FXN gene and having reduced expression of frataxin protein, the method comprising administering to the subject a therapeutically effective amount of an inhibitory nucleic acid that targets and specifically reduces expression of a FXN Repressing Factor (FXN-RF) selected from the group consisting of EZH2, EED, DNMT3A, DNMT3B, SETDB1, EHMT2/G9a, RING1B/RNF2, KDM5A, KDM5D, HDAC2, HDAC5, and SIRT7.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject has Friedreich ataxia (FA).

### Claim 6 (depends on 4)

The method of claim 4, wherein the inhibitory nucleic acid is a small interfering RNA, small hairpin RNA, or antisense oligonucleotide.

### Claim at position 7

-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the small molecule is an inhibitor of EZH2 (optionally EPZ6438, GSK126, F2880-2566; F5564-0146; F6235-0533; or F3407-3748); an inhibitor of SETDB1 and EHMT2 (optionally chaetocin); an inhibitor of KDM5A (optionally F3222-4242; F3358-0326; F3385-1519; HDM inhibitor, 2,4-PDCA; JIB04; KDM5Ai, 4-Carboxy-2-heterocyclic pyridine derivatives and pyrazole derivatives); an inhibitor of EED (optionally EED226 or A395); an HDAC inhibitor (optionally F0307-0365; F3407-0197; F6196-0976; F3095-0357; LMK235; PCI-24781; or trichostatin A (TSA)); an inhibitor of SUV39H1 (optionally F2470-0099; F2880-1734; or F3222-4478); an inhibitor of DNMT3A or DNMT3B (optionally F2578-0281; F3258-0176; or F3342-0131); or an inhibitor of SIRT7 (optionally F2721-0219; F3220-0531; F3220-0613; F3319-0778; or F3385-2786).
